CellMax Life, a Sunnyvale, CA-based precision cancer blood-testing company, raised $9M in series A-1 venture capital funding.
The round was led by Artiman and Taiwanese venture capital investors including Stan Shih, founder, and honorable chairman of Acer, Inc.
The company intends to use the funds for continued product development, ongoing clinical trials, and commercialization of the full range of blood tests, including genetic cancer risk detection, and early cancer detection for colorectal and other cancers.
Founded in 2012 by Atul Sharan, CEO, CellMax Life provides blood tests for genetic cancer risk assessment, early detection and personalized treatment of cancer, which are based on proprietary, clinically proven rare-cell and genomic technology platforms. The company’s flagship product is CellMax CRC-Protect, a multi-biomarker blood test for early detection of colorectal cancer, which is currently marketed in Taiwan.
CellMax Life is also based in Taipei City.